STAA

STAAR Surgical Company

Fundamental data last updated:October 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

 


VALUATION

P/E

-69.01

Market Cap ($M USD)

$1.45B

Forward P/E

15.47

PEG

0.03

PRICE TO SALES

4.99

PRICE TO BOOK

4.12

EV / EBITDA

91.46

5-Year Average P/E

Free Cash Flow Yield

-3.80%

DCF Value

$1.36

Graham Number

N/A

Price to FCF

-26.33

EV to FCF

-24.61

Earnings Yield

-1.45%

FCF Yield

-3.80%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.42

Next Year EPS Growth Estimate

$1.88

Next Year Revenue Growth Estimate

$530.10M

Return on Equity (ROE)

-6.07%

FREE CASH FLOW

Operating Margin

-1.72%

Debt-to-Equity

0.11

Piotroski F-Score

3

Altman Z-Score

10.33

Return on Invested Capital (ROIC)

-1.28%

Current Ratio

5.12

Quick Ratio

4.31

Net Debt to EBITDA

-6.39

Interest Coverage

0.00

Gross Profit margin

76.43%

FCF PER SHARE

$-1.10

REVENUE PER SHARE

$5.82

Gainseekers Quantitative Analysis

Summary

STAA Surgical’s valuation is a paradox. Despite a deeply negative DCF value, the market has priced it significantly above this metric, suggesting a disconnect between intrinsic value and market perception. The Forward P/E of 16.79 indicates optimism for future earnings, contrasting sharply with the current negative earnings yield. However, the Altman Z-score of 7.11 suggests financial stability, hinting at a low risk of bankruptcy. This stock is a speculative bet on future growth rather than a value play.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, STAA Surgical is well-positioned to leverage AI and modern technology. As a player in Medical Instruments & Supplies, the company can integrate AI for precision in surgical tools and enhance patient outcomes. This adaptability could provide a competitive edge in a tech-driven future.

The Bull Case

For the bullish investor, STAA offers intriguing potential. The company's low Debt/Equity ratio of 0.11 and a robust Current Ratio of 4.55 highlight financial prudence and liquidity. Despite a negative ROIC, the high Gross Profit Margin of 75.63% suggests strong pricing power. These factors, coupled with a low PEG ratio of 0.08, paint a picture of a company with potential for growth at a reasonable price.

The Bear Case

Yet, the bear case is compelling. The negative Price to FCF and an abysmal FCF Yield signal poor cash flow management. Trading near its 52-week high, the stock appears technically overextended, raising concerns about its sustainability. The negative EPS and operating margin further underscore structural weaknesses, making it a risky proposition for conservative investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$29.54

Institutional Ownership %

1-Year Beta

1.20

Insider Buying % (6 Mo)

Distance to 52-Week High

23.35%

Distance to 52-Week Low

46.39%

EARNINGS SURPRISE %

600.85%

50-DAY SMA

$25.30

200-DAY SMA

$24.29

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.